Your browser doesn't support javascript.
loading
Physical Activity Capture Technology With Potential for Incorporation Into Closed-Loop Control for Type 1 Diabetes.
Dadlani, Vikash; Levine, James A; McCrady-Spitzer, Shelly K; Dassau, Eyal; Kudva, Yogish C.
Afiliação
  • Dadlani V; Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA.
  • Levine JA; Mayo Clinic, Scottsdale, AZ, USA Obesity Solutions, Mayo Clinic Arizona and Arizona State University, Tempe, AZ, USA.
  • McCrady-Spitzer SK; Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA.
  • Dassau E; Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA, USA.
  • Kudva YC; Endocrine Research Unit, Mayo Clinic, Rochester, MN, USA kudva.yogish@mayo.edu.
J Diabetes Sci Technol ; 9(6): 1208-16, 2015 Oct 18.
Article em En | MEDLINE | ID: mdl-26481641
ABSTRACT
Physical activity is an important determinant of glucose variability in type 1 diabetes (T1D). It has been incorporated as a nonglucose input into closed-loop control (CLC) protocols for T1D during the last 4 years mainly by 3 research groups in single center based controlled clinical trials involving a maximum of 18 subjects in any 1 study. Although physical activity data capture may have clinical benefit in patients with T1D by impacting cardiovascular fitness and optimal body weight achievement and maintenance, limited number of such studies have been conducted to date. Clinical trial registries provide information about a single small sample size 2 center prospective study incorporating physical activity data input to modulate closed-loop control in T1D that are seeking to build on prior studies. We expect an increase in such studies especially since the NIH has expanded support of this type of research with additional grants starting in the second half of 2015. Studies (1) involving patients with other disorders that have lasted 12 weeks or longer and tracked physical activity and (2) including both aerobic and resistance activity may offer insights about the user experience and device optimization even as single input CLC heads into real-world clinical trials over the next few years and nonglucose input is introduced as the next advance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Glicemia / Exercício Físico / Pâncreas Artificial / Diabetes Mellitus Tipo 1 / Actigrafia / Hipoglicemiantes / Insulina / Atividade Motora Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Diabetes Sci Technol Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Glicemia / Exercício Físico / Pâncreas Artificial / Diabetes Mellitus Tipo 1 / Actigrafia / Hipoglicemiantes / Insulina / Atividade Motora Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Diabetes Sci Technol Ano de publicação: 2015 Tipo de documento: Article